[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350939-105":59,"doc-detail-350939-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","synergistic-anticancer-effects-of-lipoplex-encapsulated-q7-peptide-and-doxorubicin-against-endometrial-cancer-cells","Synergistic anticancer effects of lipoplex-encapsulated Q7 peptide and doxorubicin against endometrial cancer cells","","Endometrial cancer is a major gynecological malignancy with rising incidence and limited options for advanced disease. Q7 was previously shown to suppress DHCR24, regulate the AKT pathway, and trigger apoptosis in HEC-1-A cells. Here, Q7 inhibits proliferation, migration, and invasion, potentially via lipid metabolism and cytoskeletal remodeling, suppressing tumor motility despite transient early EMT gene upregulation. Encapsulating Q7 in lipoplex nanoparticles (LPPC-Q7) strengthens anti-tumor activity in vitro and in vivo. Combining LPPC-Q7 with doxorubicin (LPPC-Q7-DOX) yields synergistic tumor growth suppression, enhanced apoptosis, and reduced exosome production and metastasis.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/synergistic-anticancer-effects-of-lipoplex-encapsulated-q7-peptide-and-doxorubicin-against-endometrial-cancer-cells/350939/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/synergistic-anticancer-effects-of-lipoplex-encapsulated-q7-peptide-and-doxorubicin-against-endometrial-cancer-cells/350939.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How does the Q7 peptide exert anticancer effects in endometrial cancer cells?","Question",{"text":113,"@type":114},"Q7 suppresses DHCR24, regulates AKT pathway activity, and induces apoptosis. It also inhibits proliferation, migration, and invasion, involving lipid metabolism and cytoskeletal remodeling pathways.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why was Q7 encapsulated into lipoplex nanoparticles (LPPC-Q7)?",{"text":118,"@type":114},"Q7 has in vivo instability, so lipoplex encapsulation using the Lipo-PEG-PEI complex (LPPC) is used to increase half-life and strengthen antitumor effects, including effects against drug resistance.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the added benefit of combining LPPC-Q7 with doxorubicin (LPPC-Q7-DOX)?",{"text":122,"@type":114},"LPPC-Q7-DOX produces a synergistic effect, improving tumor growth suppression and apoptosis induction while inhibiting exosome production and metastasis.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350939,1790928291,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSynergistic anticancer effects of lipoplex-encapsulated Q7 peptide and doxorubicin against endometrial cancer cells  \nChia-Hung Chen1,2, Hui-Ju Kao1,2, Tzu-Hsiang Weng3, Chen-Lin Yu1,2, Yu-Chi Chen1,2,  \nChen-Chen Huang1,2, Kuang-Wen Liao4,5, Kai-Yao Huang1,2,6,7􀀍 & Shun-Long Weng4,6,8,9,10􀀍  \nEndometrial cancer remains a major gynecological malignancy with a rising incidence and limited treatment options for advanced cases. Our previous study demonstrated that the Q7 anticancer peptide exerts its effects by suppressing DHCR24, regulating theAKT pathway, and inducing apoptosis in HEC-1-A endometrial cancer cells. In this study, Q7 significantly inhibits proliferation, migration, and invasion, potentially by modulating lipid metabolism and cytoskeletal remodeling pathways. Notably, Q7 transiently upregulates epithelial-mesenchymal transition (EMT)-related genes at early time points but ultimately suppresses tumor motility. To enhance its therapeutic efficacy, we encapsulated Q7 in lipoplex nanoparticles (LPPC-Q7), which exhibited superior tumor-suppressive effects both in vitro and in vivo. Furthermore, combining LPPC-Q7 with doxorubicin (LPPC-Q7-DOX) produced a synergistic effect, leading to enhanced tumor growth suppression, apoptosis induction, and inhibition of exosome production and metastasis. These findings highlight LPPC-Q7-DOX as a promising therapeutic strategy for endometrial cancer, effectively targeting lipid metabolism and cytoskeletal dynamics to combat tumor progression.  \nKeywords Endometrial cancer, Anticancer peptide, Epithelial-mesenchymal transition (EMT), Lipoplex, Synergistic effect  \nEndometrial cancer (EC) is the sixth most common cancer among women all over the world, and its incidence has increased dramatically over the past two decades1–3. According to an analysis by the International Agency for Research on Cancer, the global incidence of endometrial cancer has increased rapidly since 2018, and the number of cancer cases is expected to be 2040 will increase by more than 50%4. Early-stage disease is the most common disease, and its associated 5‐year overall survival (OS) is 81% . However, the 5‐year OS for stage IVA and IVB EC is only 17% and 15%, respectively5. Several literatures point out that metabolic abnormalities provide more nutrients to promote the deterioration of tumor cells. For example, cholesterol metabolism is positively correlated with the high incidence of cancers such as endometrial cancer, colon cancer, and liver cancer6–8. Lipid rafts and caveolae, rich in cholesterol, are responsible for important information transmission9. In several cancers, including endometrial cancer, an increase in the proportion of cholesterol in lipid rafts can activate the PI3K/AKT/mTOR signaling pathway, enhancing the tumor’s ability to proliferate, metastasize, and invade8. Therefore, effectively inhibiting or regulating the activity of the PI3K/AKT/mTOR signal pathway is a good strategy for treating endometrial cancer10–12. An anticancer peptide Q7, screened by the iDACP website13, was a positive charge short-chain peptide composed of 15 amino acids, and the amino acid sequence  \n1Department of Medical Research, Hsinchu MacKay Memorial Hospital, Hsinchu 30071, Taiwan, ROC. 2Department of Medical Research, Hsinchu Municipal MacKay Children’s Hospital, Hsinchu 30068, Taiwan, ROC. 3Department of Obstetrics and Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan, ROC. 4Department of Biological Science and Technology, College of Engineering Bioscience, National Yang Ming Chiao Tung University, Hsinchu 30068, Taiwan, ROC. 5Institute of Molecular Medicine and Bioengineering, College of Engineering Bioscience, NationalYang Ming Chiao Tung University, Hsinchu 30068, Taiwan, ROC. 6Department of Medicine, MacKay Medical College, No.46, Sec. 3, Zhongzheng Rd., Sanzhi Dist, New Taipei 25245, Taiwan, ROC. 7Institute of Biomedical ","cbCaivO7gxiG6CI9","https://ap.wps.com/l/cbCaivO7gxiG6CI9","pdf",4142202,15,"English","# Introduction\n## Clinical challenge in endometrial cancer\n## Metabolic regulation, lipid rafts, and PI3K/AKT/mTOR\n## Q7 peptide background and rationale\n# Combination therapy concept\n## Targeted agents and synergy\n# Delivery strategy and study direction\n## Lipoplex (LPPC) encapsulation","[{\"question\":\"How does the Q7 peptide exert anticancer effects in endometrial cancer cells?\",\"answer\":\"Q7 suppresses DHCR24, regulates AKT pathway activity, and induces apoptosis. It also inhibits proliferation, migration, and invasion, involving lipid metabolism and cytoskeletal remodeling pathways.\"},{\"question\":\"Why was Q7 encapsulated into lipoplex nanoparticles (LPPC-Q7)?\",\"answer\":\"Q7 has in vivo instability, so lipoplex encapsulation using the Lipo-PEG-PEI complex (LPPC) is used to increase half-life and strengthen antitumor effects, including effects against drug resistance.\"},{\"question\":\"What is the added benefit of combining LPPC-Q7 with doxorubicin (LPPC-Q7-DOX)?\",\"answer\":\"LPPC-Q7-DOX produces a synergistic effect, improving tumor growth suppression and apoptosis induction while inhibiting exosome production and metastasis.\"}]","Synergistic anticancer effects of lipoplex-encapsulated Q7 peptide and doxorubicin against endometrial cancer cells | PDF",1790091871,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b017e0148538e99f33184e5523e089fc.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/072be215d78cec6f4e92db600efc7007.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/919ec70468ec8c8905c7d24fd9a4e94c.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75637191ab6954ae0b3028e3831a81ae.webp",980,1287]